Multiple Sclerosis [2016]: Bulletin #2
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus (ocrelizumab, Roche/Biogen) as a therapy for relapsing and primary progressive forms of MS; AB Science announcing that its oral tyrosine kinase inhibitor, masitinib, has passed the two-year non-futility test in a Phase III trial; and Apitope announcing positive results from a Phase IIa clinical trial of ATX-MS-1467, a peptide-based therapy with potential in MS.
Business Questions
Business Questions
- According to KOLs, what are the chances of Ocrevus being approved with the same broad label in the EU?
- How likely is it that Ocrevus be prescribed off-label?
- Which product(s) will be most impacted by Ocrevus’ launch?
- What are KOLs’ opinions regarding masitinib and where in the treatment paradigm would such an agent be used?
- How clinically attractive is Apitope’s ATX-MS-1467?
